Fenofibrate plus simvastatin in combined dyslipidemia: pros and cons
What is it about?
Dear all, the article "Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy" concerns a very interesting and daily topic. Either you have not clear ideas of pro and cons of double lipid lowering agents therapy, or you need confirmation about how to manage this daily medical issue, this REVIEW and METANALYSIS is what you were waiting for.
Why is it important?
Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy is: - very USEFUL and easily understandble - very COMPLETE review and metanalysis - UPDATED to the last researches and trials -rich of new and fresh unpublished explicative FIGURES - addresssed not only to CARDIOLOGISTS or specialists in INTERNAL MEDICINE, but also physician specialized in INFECTIOUS DISEASE, ENDOCRINOLOGY and PEDIATRICS (appropriate sections are present in) - addressed for GENERAL physician too - MEDICAL STUDENTS can find it very HELPFUL for their exams or thesis
The following have contributed to this page: Natale Daniele Brunetti, Dr Nicola Tarantino, and Dr Michele Correale